$QNCX
Quince Therapeutics, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022009040 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.060M $9.110M $8.330M
YoY Change 28.33% 40.37% 66.6%
% of Gross Profit
Research & Development $7.199M $12.76M $15.21M
YoY Change -51.09% -24.17% -4.1%
% of Gross Profit
Depreciation & Amortization $80.00K $40.00K $80.00K
YoY Change 0.0% -55.56% 0.0%
% of Gross Profit
Operating Expenses $16.26M $21.86M $23.54M
YoY Change -25.36% -6.22% 12.9%
Operating Profit -$16.26M -$21.86M
YoY Change -25.36% -6.22%
Interest Expense $150.0K $70.00K $110.0K
YoY Change -6.25% -69.57% -63.33%
% of Operating Profit
Other Income/Expense, Net -$735.0K $150.0K $40.00K
YoY Change 461.07%
Pretax Income -$16.85M -$21.64M -$23.40M
YoY Change -22.53% -6.28% 13.81%
Income Tax -$284.0K $0.00
% Of Pretax Income
Net Earnings -$16.56M -$21.64M -$23.40M
YoY Change -23.86% -6.26% 13.81%
Net Earnings / Revenue
Basic Earnings Per Share -$0.51 -$0.72
Diluted Earnings Per Share -$0.51 -$0.72 -$0.78
COMMON SHARES
Basic Shares Outstanding 30.15M 30.15M 29.88M
Diluted Shares Outstanding 32.47M 30.13M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.70M $64.12M $66.53M
YoY Change -27.13% -56.39% -50.28%
Cash & Equivalents $46.93M $40.16M $29.45M
Short-Term Investments $54.80M $23.96M $37.08M
Other Short-Term Assets $4.800M $487.0K $367.0K
YoY Change 995.89% -12.57% -47.12%
Inventory
Prepaid Expenses $352.0K $333.0K
Receivables
Other Receivables
Total Short-Term Assets $99.40M $96.35M $111.7M
YoY Change -26.83% -35.72% -19.0%
LONG-TERM ASSETS
Property, Plant & Equipment $700.0K $230.0K $263.0K
YoY Change 79.49% -39.15% -38.41%
Goodwill $825.0K $0.00
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments $11.00M $19.20M $19.90M
YoY Change -53.19% -18.99% -60.59%
Other Assets $0.00 $29.00K $194.0K
YoY Change -100.0% -25.64% 397.44%
Total Long-Term Assets $18.50M $19.78M $21.56M
YoY Change -27.58% -19.73% -58.23%
TOTAL ASSETS
Total Short-Term Assets $99.40M $96.35M $111.7M
Total Long-Term Assets $18.50M $19.78M $21.56M
Total Assets $117.9M $116.1M $133.2M
YoY Change -26.95% -33.46% -29.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.900M $3.731M $4.911M
YoY Change -73.59% 31.14% 38.14%
Accrued Expenses $4.000M $5.979M $9.311M
YoY Change -64.74% -60.2% -30.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K
YoY Change
Total Short-Term Liabilities $6.000M $9.710M $14.22M
YoY Change -67.63% -45.65% -16.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $0.00 $400.0K
YoY Change -87.5% -100.0% 100.0%
Total Long-Term Liabilities $100.0K $0.00 $400.0K
YoY Change -87.5% -100.0% 100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.000M $9.710M $14.22M
Total Long-Term Liabilities $100.0K $0.00 $400.0K
Total Liabilities $6.300M $9.750M $14.64M
YoY Change -67.37% -45.83% -14.89%
SHAREHOLDERS EQUITY
Retained Earnings -$258.2M -$236.6M
YoY Change 52.15% 61.33%
Common Stock $365.1M $355.3M
YoY Change 11.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $111.5M $106.4M $118.6M
YoY Change
Total Liabilities & Shareholders Equity $117.9M $116.1M $133.2M
YoY Change -26.95% -33.45% -29.68%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$16.56M -$21.64M -$23.40M
YoY Change -23.86% -6.26% 13.81%
Depreciation, Depletion And Amortization $80.00K $40.00K $80.00K
YoY Change 0.0% -55.56% 0.0%
Cash From Operating Activities -$15.42M -$16.09M -$14.42M
YoY Change -12.19% 18.23% 8.58%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $5.000K $40.00K
YoY Change -100.0% -86.49% 300.0%
Acquisitions
YoY Change
Other Investing Activities -$5.250M $13.42M $20.96M
YoY Change -191.78% -57.64% 32.32%
Cash From Investing Activities -$5.250M $13.41M $20.92M
YoY Change -193.25% -57.61% 32.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $608.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 110.0K 622.0K 990.0K
YoY Change -83.58% 41.04% 1880.0%
NET CHANGE
Cash From Operating Activities -15.42M -16.09M -14.42M
Cash From Investing Activities -5.250M 13.41M 20.92M
Cash From Financing Activities 110.0K 622.0K 990.0K
Net Change In Cash -20.56M -2.160M 7.490M
YoY Change 82.59% -111.69% 188.08%
FREE CASH FLOW
Cash From Operating Activities -$15.42M -$16.09M -$14.42M
Capital Expenditures $0.00 $5.000K $40.00K
Free Cash Flow -$15.42M -$16.10M -$14.46M
YoY Change -12.68% 17.95% 8.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 crtx Operating Lease Termination Month And Year
OperatingLeaseTerminationMonthAndYear
2021-07
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001662774
CY2020Q2 crtx Operating Lease Termination Month And Year
OperatingLeaseTerminationMonthAndYear
2021-07
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38890
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Cortexyme, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-1024039
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
269 East Grand Ave.
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022Q1 dei City Area Code
CityAreaCode
415
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
910-5717
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
CRTX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30150835
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67564000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69724000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
23960000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
37078000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4829000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4871000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
96353000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
111673000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
230000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
263000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
343000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1165000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
19175000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
19933000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
194000
CY2022Q1 us-gaap Assets
Assets
116130000
CY2021Q4 us-gaap Assets
Assets
133228000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3731000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4911000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5979000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9311000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9710000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14222000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
420000
CY2022Q1 us-gaap Liabilities
Liabilities
9750000
CY2021Q4 us-gaap Liabilities
Liabilities
14642000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30149570
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30149570
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30074412
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30074412
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
30000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
365096000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
355234000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-506000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-79000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-258240000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-236599000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
106380000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
118586000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116130000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
133228000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12757000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16824000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9106000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6489000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
21863000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
23313000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21863000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23313000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
72000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
227000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
150000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21641000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-23086000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-114000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-313000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-124000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22068000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23210000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13413000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31643000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30134445
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29554921
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
118586000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
608000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9240000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-313000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21641000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
106380000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172262000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
441000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6991000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-124000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-23086000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
156484000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-21641000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-23086000
CY2022Q1 crtx Non Cash Rent Expense
NonCashRentExpense
0
CY2021Q1 crtx Non Cash Rent Expense
NonCashRentExpense
92000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9240000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6991000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
38000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
86000
CY2022Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-135000
CY2021Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-202000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-42000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1192000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-165000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1180000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-710000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2890000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1623000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16091000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13610000
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
8957000
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
11980000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
22375000
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
43660000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67564000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85315000
CY2022Q1 crtx Right Of Use Asset And Operating Lease Liability Reduction As A Result Of Lease Modification
RightOfUseAssetAndOperatingLeaseLiabilityReductionAsAResultOfLeaseModification
-640000
CY2021Q1 crtx Right Of Use Asset And Operating Lease Liability Reduction As A Result Of Lease Modification
RightOfUseAssetAndOperatingLeaseLiabilityReductionAsAResultOfLeaseModification
0
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
441000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
608000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
622000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
441000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66841000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-104000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2160000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18474000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69724000
CY2022Q1 crtx Entity Date Of Incorporation
EntityDateOfIncorporation
2012-06
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-258200000
CY2022Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
91500000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
19200000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company’s consolidated financial statements relate to the determination of the fair value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets, eligibility of expenses for the Australia research and development refundable tax credits; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company’s estimates.</span></p>
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
23960000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
19175000
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
83296000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
86564000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
18000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
117000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
86465000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29454000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
37078000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
19933000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
86465000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
83296000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
86465000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
83708000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
415000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
83296000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40161000
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
0
CY2022Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2022Q1 crtx Available For Sale Securities Gross Realized Gains Or Losses
AvailableForSaleSecuritiesGrossRealizedGainsOrLosses
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
67564000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
69724000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
23960000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
37078000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
19175000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
19933000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
352000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
333000
CY2022Q1 crtx Prepaid Insurance Current
PrepaidInsuranceCurrent
385000
CY2021Q4 crtx Prepaid Insurance Current
PrepaidInsuranceCurrent
1144000
CY2022Q1 crtx Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2047000
CY2021Q4 crtx Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
1899000
CY2022Q1 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
1558000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
1128000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
487000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
367000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4829000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4871000
CY2021 crtx Reductions In Research And Development Expense
ReductionsInResearchAndDevelopmentExpense
1100000
CY2022Q1 crtx Reductions In Research And Development Expense
ReductionsInResearchAndDevelopmentExpense
400000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
996000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
959000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
230000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
263000
CY2022Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1213000
CY2021Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
820000
CY2022Q1 us-gaap Severance Costs1
SeveranceCosts1
261000
CY2021 us-gaap Severance Costs1
SeveranceCosts1
0
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
600000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
462000
CY2022Q1 crtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3485000
CY2021Q4 crtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
7108000
CY2022Q1 crtx Accrued Operating Lease Liabilities Current
AccruedOperatingLeaseLiabilitiesCurrent
299000
CY2021Q4 crtx Accrued Operating Lease Liabilities Current
AccruedOperatingLeaseLiabilitiesCurrent
741000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
121000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
180000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5979000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9311000
CY2022Q1 crtx Percentage Of Reduction In Workforce
PercentageOfReductionInWorkforce
0.53
CY2022Q1 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
1900000
CY2021Q1 us-gaap Severance Costs1
SeveranceCosts1
0
CY2021Q4 crtx Accrued Severance
AccruedSeverance
0
CY2022Q1 crtx Accrued Severance Incurred
AccruedSeveranceIncurred
1687000
CY2022Q1 crtx Accrued Severance Paid
AccruedSeverancePaid
-1426000
CY2022Q1 crtx Accrued Severance
AccruedSeverance
261000
CY2018Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2018Q2 crtx Repurchase Option Percentage
RepurchaseOptionPercentage
1
CY2018Q2 crtx Operating Leases Period
OperatingLeasesPeriod
P3Y
CY2019Q2 crtx Operating Lease Payments Paid For Additional Space
OperatingLeasePaymentsPaidForAdditionalSpace
63000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
0
CY2019Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
172000000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1200000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44000000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1300000
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
640000000
CY2022Q1 crtx Payments For Security Deposit
PaymentsForSecurityDeposit
105000
CY2022Q1 crtx Operating Lease Future Rent Expense
OperatingLeaseFutureRentExpense
329000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
343000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1165000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
299000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
741000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
420000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
339000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1161000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0234
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0187
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
272000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
70000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
342000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
339000
CY2022Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
57100000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M3D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Based Liabilities Paid
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid
3600000
CY2022Q1 crtx Lifetodateexpense
Lifetodateexpense
1600000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9240000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6991000
CY2022Q1 crtx Provision For Income Taxes
ProvisionForIncomeTaxes
0
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7511898
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5531521

Files In Submission

Name View Source Status
0000950170-22-009040-index-headers.html Edgar Link pending
0000950170-22-009040-index.html Edgar Link pending
0000950170-22-009040.txt Edgar Link pending
0000950170-22-009040-xbrl.zip Edgar Link pending
crtx-20220331.htm Edgar Link pending
crtx-20220331.xsd Edgar Link pending
crtx-20220331_cal.xml Edgar Link unprocessable
crtx-20220331_def.xml Edgar Link unprocessable
crtx-20220331_htm.xml Edgar Link completed
crtx-20220331_lab.xml Edgar Link unprocessable
crtx-20220331_pre.xml Edgar Link unprocessable
crtx-ex31_1.htm Edgar Link pending
crtx-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending